What is Savara Inc (SVRA) stock price today?

Savara Inc (SVRA) currently trades at $5.12 per share. The stock has a market capitalization of $1.06B and a P/E ratio of —x.

Is SVRA stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Savara Inc has a Smart Value Score of 23/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 1/9 and Altman Z-Score is -1.60.

What is Savara Inc's revenue and earnings?

Savara Inc has trailing twelve-month (TTM) revenue of $1000.00 with profit margins of 0.00%. Earnings per share (EPS) is $-0.53.

Is Savara Inc financially healthy?

Savara Inc's Piotroski F-Score is 1/9 (weak financial health). The Altman Z-Score of -1.60 places it in the distress.

SVRA

Savara Inc

NASDAQ: SVRA · HEALTHCARE · BIOTECHNOLOGY

$5.12

-2.10% today

Updated 2026-05-11

Market cap

$1.06B

P/E ratio

—

P/S ratio

145,272.62x

EPS (TTM)

$-0.53

Dividend yield

—

52W range

$2 – $7

Volume

1.5M

Market cap

$1.06B

P/E ratio

—

P/S ratio

145,272.62x

EPS (TTM)

$-0.53

Dividend yield

—

52W range

$2 – $7

Volume

1.5M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

5.5

Quality

C+

3.0

Profitability

5.0

Valuation

C+

1/9

Piotroski F-Score

Weak

-1.6

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →198 stocks currently score above 75

Price targets

Analyst target

$10.81

+111.13%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

2 Strong Buy6 Buy0 Hold0 Sell0 Strong Sell

Price chart

Stock snapshot

Strengths

+ Debt/equity 0.32x — low leverage

Risks

- Piotroski 1/9 — weak financial health

- Altman Z -1.60 — distress zone

- Thin margins at 0.00%

- Negative free cash flow $-25.06M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$0.00	$0.00	$0.00	$0.00	$1000.00
Net income	$-38.15M	$-54.70M	$-95.88M	$-118.84M	$-32.24M
EPS	—	—	—	—	$-0.53
Free cash flow	$-34.56M	$-51.36M	$-89.11M	$-101.06M	$-25.06M
Profit margin	—	—	—	—	—

Recent insider activity

Date	Insider	Type	Shares	Price
2026-03-18	LOWRANCE, DAVID L	Sale	130,650	—
2026-03-18	LOWRANCE, DAVID L	Sale	80,684	—
2026-03-18	LOWRANCE, DAVID L	Sale	75,000	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
SVRA	$1.06B	23	4.3	3.0	5.0	5.5	—	Avoid
LLY	$869.41B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$535.63B	59	4.7	9.0	3.3	6.0	-37.47%	Buy
ABBV	$358.55B	63	4.0	8.0	4.0	5.0	-19.74%	Buy
UNH	$335.78B	54	5.3	5.5	7.3	4.8	+40.60%	Buy
AZN	$283.47B	62	6.0	8.5	5.3	5.0	+6.51%	Buy

Smart narrative

Savara Inc trades at $5.12. Our Smart Value Score of 23/100 indicates the stock is weak. The company scores 1/9 on the Piotroski F-Score. With an Altman Z-Score of -1.60, it sits in the distress. TTM revenue stands at $1000.00.

Frequently asked questions

What is Savara Inc's stock price?

Savara Inc (SVRA) trades at $5.12.

Is Savara Inc overvalued?

Smart Value Score 23/100 (Grade F, Strong Sell).

What is the price target of Savara Inc (SVRA)?

The analyst target price is $10.81, representing +111.1% upside from the current price of $5.12.

What is Savara Inc's revenue?

TTM revenue is $1000.00.

Piotroski F-Score?

1/9 — weak financial health.

Altman Z-Score?

-1.60 — distress.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

www.savarapharma.com

Quick metrics

P/S ratio145,272.62x

ROE-63.40%

Beta0.28

50D MA$5.41

200D MA$4.75

Shares out0.20B

Float0.13B

Short ratio—

Avg volume1.5M

Performance

1 week-0.78%

1 month-7.91%

3 months-7.25%

YTD-15.09%

1 year—

3 years—

5 years—

Compare

SVRA vs LLY →SVRA vs JNJ →SVRA vs ABBV →Stock screener →